Nemsadze G

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 66 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Non-Small Cell Lung Cancer with PD-L1 ≥ 1 %: A Subgroup Analysis from the EMPOWER-Lung 3 Part 2 Trial

Ana Baramidze,Tamta Makharadze,Miranda Gogishvili,Tamar Melkadze,Davit Giorgadze,Konstantin Penkov,Konstantin Laktionov,Gia Nemsadze,Marina Nechaeva,Irina Rozhkova,Ewa Kalinka,Debra A. G. McIntyre, Javier Perez,Manika Kaul,Ruben G. W. Quek,Frank Seebach,Petra Rietschel,Jean-Francois Pouliot

LUNG CANCER (2024)

引用0浏览0WOS引用

Abstract RF01-01: SERENA-3: A Randomized Pre-Surgical Window of Opportunity Study Assessing Dose and Duration of Camizestrant Treatment in Post-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer

John Robertson, Teimuraz Gogitidze, Zaza Katashvili,Juan Enrique Bargalló Rocha,Ekaterine Arkania,I. K. Moppett, Kwok‐Leung Cheung,Gia Nemsadze,Maxine Ajimi,Itziar Irurzun‐Arana,Justin P.O. Lindemann,Teresa Klinowska,Alastair Mathewson,Christopher J. Morrow,Myria Nikolaou,Giorgi Dzagnidze

Cancer researchno. 9_Supplement (2024): RF01-01

引用0浏览0引用

2MO Dynamics of ESR1 Mutation (esr1m) Circulating Tumour DNA (ctdna) in Patients (pts) with Estrogen Receptor (ER)+ HER2- Metastatic Breast Cancer (mbc) Receiving Camizestrant or Fulvestrant: Exploratory Analyses from the SERENA-2 Trial

M. Oliveira,E.P. Hamilton, Y. Kulyaba,T. Melkadze, P. Neven,G. Nemsadze, T. Andabekov, C. Zamagni, V.I. Vladimirov, M. Ajimi, C. Ciardullo, I. Gioni,T. Klinowska, J. Lindemann,R. McEwen, C. Morrow,E. Arkania

ESMO Open (2024)

引用0浏览0引用

274P A Multiomic Approach for Camizestrant-Induced Estrogen Receptor (ER) Degradation, Antagonism and Anti-Proliferation: Exploratory Analysis from SERENA-3

G. Dzagnidze, C. Morrow, T. Gogitidze, Z.S. Katashvili,J.E. Bargallo Rocha,E. Arkania, I. Moppett, K-L. Cheung,G. Nemsadze, M. Ajimi, K. Andreou, A. Chambers, D. Chain, R. Kim, J. Lindemann,R. Mcewen, M. Nikolaou, J. Robertson, D. Whitston, J.F. Robertson

Annals of Oncology (2024)

引用0浏览0引用

Abstract RF01-01: SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer